14 results
8-K
EX-99.1
GLYC
GlycoMimetics Inc
1 Mar 24
Regulation FD Disclosure
9:16am
= time to discharge; TTDIVO = time to discontinuation of IV opioids; CIVO = cumulative IV opioid use Dampier et al, Blood 2023 Early Treatment Resulted
8-K
EX-99.1
GLYC
GlycoMimetics Inc
4 Oct 22
Regulation FD Disclosure
5:03pm
Benefit 17 TTRD = time to readiness for discharge; TTD = time to discharge; TTDIVO = time to discontinuation of IV opioids; CIVO = cumulative IV opioid
8-K
EX-99.1
GLYC
GlycoMimetics Inc
5 Aug 19
Glycomimetics Reports Top-line Results from Pfizer’s Phase 3 Clinical Trial Evaluating Rivipansel In Sickle Cell Disease
4:30pm
and the key secondary efficacy endpoints were time-to-discharge, cumulative IV opioid consumption, and time to discontinuation of IV opioids.
“We are both
8-K
EX-99.1
GLYC
GlycoMimetics Inc
25 Jul 18
Regulation FD Disclosure
8:30am
) Time to Discharge From Hospital Time to Resolution of VOC GlycoMimetics, Inc.
Phase 2 Results - Significant Reduction in Opioid Use Hourly IV Opioid … Use Mean Hourly Opioid Use Rivipansel Placebo 24 hour reduction p<0.001 *** Cumulative opioid analgesic administered reduced by 83% (p=0.010) 10
10-K
r627o2yvksmxltjcb
31 Mar 14
Annual report
12:00am
424B4
0t5 4q3bstgxx4f6
10 Jan 14
Prospectus supplement with pricing info
12:00am
S-1
5lc65f
4 Oct 13
IPO registration
12:00am
- Prev
- 1
- Next